New hope for rare tumor disorder: belzutifan trial launches
Disease control
Recruiting now
This study is for people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in the brain, kidneys, pancreas, and other organs. Researchers want to see how well the drug belzutifan shrinks or controls these tumors and what side effects it may cause. Abou…
Phase: PHASE2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated May 07, 2026 18:39 UTC